The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Congresses
Poster
T-DXd
ESMO Breast 2026 | May 6-8, 2026
Breast Cancer
A multicenter, retrospective study to determine the prevalence of HER2-low & associated outcomes in patients previously identified with HER2 negative locally advanced (LA) or metastatic breast cancer (mBC) who progressed on systemic anticancer therapy: Interim analysis of iRetroBC-HER2L study
Senthil Rajappa
View presentation
Oral
Dato-DXd
ESMO Breast 2026 | May 6-8, 2026
Breast Cancer
First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option: Patient-reported outcomes (PROs) from TROPION-Breast02
Peter Schmid
View presentation
Oral
HER3-DXd
ESMO Breast 2026 | May 6-8, 2026
Breast Cancer
HER3 expression and overall survival (OS) in ICARUS-BREAST01: A phase 2 study of patritumab deruxtecan (HER3-DXd) in patients with HR+/HER2- advanced breast cancer
Cecile Vicier
View presentation
Poster
T-DXd
ESMO Breast 2026 | May 6-8, 2026
Breast Cancer
Improved accuracy and consistency in breast cancer HER2 scoring using an AI-based diagnostic solution: Multi-site validation supporting CE-IVDR certification
Frederik Deman
View presentation
Poster
T-DXd
ESMO Breast 2026 | May 6-8, 2026
Breast Cancer
Real-world data on effectiveness of trastuzumab deruxtecan (T-DXd) in central nervous system metastases (CNSm) in HER2+ previously treated metastatic breast cancer: Subgroup analysis of REALITY-01 study
Louis Larrouquere
View presentation
Oral
T-DXd
ESMO Breast 2026 | May 6-8, 2026
Breast Cancer
Residual cancer burden (RCB) following neoadjuvant treatment with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP in high-risk, HER2+ early-stage breast cancer
Lajos Pusztai
View presentation
Poster
T-DXd
ESMO Breast 2026 | May 6-8, 2026
Breast Cancer
The value of experiencing deep partial response in the context of long-term outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A DESTINY-Breast03 exploratory analysis
Erika Hamilton
View presentation
Poster
T-DXd
ESMO Breast 2026 | May 6-8, 2026
Breast Cancer
Trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer and active brain metastases: Final analysis of DESTINY-Breast07
Carey Anders
View presentation
Connect with an MSL
Linkedin Icon Twitter Icon

©2026  Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24